

AstraZeneca Corporate Social Responsibility Report 2000



(including the Annual Safety,
Health and Environment Report)

Contents

Executive message	3
Sustainable development	4
Delivering our policies	5
Health and Safety Performance	6
Employee development and consultation	8
Wellbeing	8
Care and Use of Laboratory Animals	9
R&D Investment in Bangalore, India	9
Environmental performance	10
Benchmarking	10
Use of resources	10
Waste	10
Water Use	11
Discharges to the Environment	11
Water	11
Air	11
Energy & Global warming	12
Transport	12
Compliance	13
Pharmaceuticals in the Environment	13
Other Issues	13
Chief Executive's Awards	14
Policy & Code of Conduct	15
Contacts	16



- Research & Development
- Manufacturing

Introduction

Welcome to AstraZeneca's Corporate Social Responsibility Report 2000. For the first time, we have expanded our annual report on safety, health and environmental performance to include some information on other areas of corporate responsibility. We intend to extend our reporting on social issues progressively in line with the recommendations of the Global Reporting Initiative. This printed report is a summary of the complete report which is available on our website: www.astrazeneca.com

Scope

Following the creation of AstraZeneca in April 1999, we introduced a new SHE reporting system that covers all of our facilities worldwide. We will be using it to monitor our SHE performance in the future. The data for 2000 is the baseline against which our future performance will be compared.

Unfortunately our 2000 data cannot be readily compared with previous years because the comprehensive systems used by the heritage companies Astra AB and Zeneca Group PLC were different.

This report covers all the facilities related to our healthcare businesses and Marlow Foods. Businesses that have been divested from the company during 2000 are excluded.

Profile

AstraZeneca is one of the world's leading pharmaceutical companies which provides innovative, effective products to fight disease in important areas of medical need. Our company is research and technology intensive, with extensive international development and marketing skills. Our business is focused on seven major therapeutic areas: cardiovascular, central nervous system, gastrointestinal, infection, oncology, pain control and anaesthesia, and respiratory.

We have worldwide operations with corporate headquarters in London, UK; research and development (R&D) headquarters in Södertälje, Sweden; and a strong presence in the key US market.

AstraZeneca sells products in over 100 countries, manufactures in 19 countries and operates six major research centres. We have over 50,000 employees worldwide.

Message from Tom McKillop, Chief Executive



The impact on society of AstraZeneca's activities is a fundamental company consideration and we aim to set, promote and maintain high standards of corporate social responsibility worldwide. Earning and maintaining society's trust and confidence is essential to our continued success.

We have key policies in place which support this aim, and we are currently reviewing our activities worldwide to ensure we can demonstrate that we are acting appropriately and consistently in all markets. This review includes developing a global strategic approach to corporate social responsibility for the company and areas for improvement.

At the core of our corporate responsibility agenda is our commitment to good safety, health and environmental performance, which is as strong as ever. Backed by a clear policy and set of standards, we have programmes in place that are beginning to deliver improvements. You can see the results here and monitor our progress in the future.

As well as the SHE information, you will find details in this summary and on our website of our approach to a range of social issues, together with examples of how we are helping to make a difference in the communities around us.

A recent initiative of which I am especially proud is our \$10 million capital investment in India to create a centre of excellence at our research facility in Bangalore for the discovery and development of new medicines of importance to the developing world. In particular, work will focus on finding a new treatment for tuberculosis, a disease that currently affects two million people every year in India and 16 million people worldwide.

Corporate social responsibility is not an add-on extra – it is an integral part of all that we do and I am determined that we will continue to be a company that is welcomed as a valued member of the global community.

AstraZeneca's corporate SHE objectives for 2001/2002

Objective 1: We will aim to improve the safety, health and wellbeing of all our employees by introducing behaviour-based programmes at all locations before July 1st 2002.

Objective 2: Our goal is to have no accidents or incidents and to minimise our environmental impact. During 2001 we will identify the key areas where improvement is a priority and the most useful indicators to measure our progress. Progress against these Key Performance Indicators will be published from 2002 onwards.

Objective 3: We will publish information about our SHE performance using the internationally recognised guidelines produced by the Global Reporting Initiative (GRI).

Objective 4: Auditing is an essential part of continuous improvement. We began a Global SHE Management Audit programme on April 1st and programmes for local SHE audits will be in place at all locations by the end of 2001.

Objective 5: We will aim to achieve a reduction in the growth of CO₂ emissions from our facilities by 2005 – this will be by an amount equivalent to 20% of 1998 emissions.

Sustainable Development

in the
Pharmaceuticals Industry

What is Sustainable Development?

Sustainable development has been defined as economic activity that meets the needs of the present generation without compromising the ability of future generations to meet their own needs. Sustainability is frequently being viewed as the achievement of a balance between the sometimes conflicting priorities of three components: economic, social and environmental.



Economic sustainability

We exist to provide good returns to our shareholders – in doing so we create employment, generate wealth and pay taxes. The pharmaceuticals industry relies on high levels of investment in research and development to ensure its continuing economic sustainability. Detailed economic information about AstraZeneca can be found in our Annual Report & Form 20-F.

Environmental sustainability

The objective of environmental sustainability is to reduce society's impact on the planet to a minimum in order to ensure that future generations have the

natural resources they need to prosper. The issues most relevant to AstraZeneca are:

- climate change (resulting from energy use)
- ozone depletion (resulting from the use of some products)
- photochemical smog formation (resulting from emissions of volatile organic compounds (VOCs))
- impact on water resources (resulting from the use of water in manufacturing and emissions of waste water).

Our environmental programme addresses all these issues and we expect to achieve continuous improvement. However, in reality, this will be constrained by technical and economic factors.

Social sustainability

The objective of social sustainability is to provide a better quality of life for all members of society. In order to make our contribution to this objective we need to understand the changing expectations of society. Our social objectives can be more clearly identified by considering all of our stakeholders – employees, customers, shareholders and the wider community – and the impact, both positive and negative, that our operations could have on them.


Significant social issues for the pharmaceutical industry include, amongst others:

- employee health and safety;
- employee development and consultation;
- access to medicines in the developing world;
- public concern about animal testing;
- gene-based medicines.

We are continuing to address these and other issues, and we report on our progress in some of these areas in this report.

Delivering our Policies

We have a number of key policies in place to ensure that we act appropriately and consistently worldwide. Agreed by our Board of Directors, they apply to all employees and activities, and compliance with them is mandatory. Our Safety, Health & Environmental (SHE) Policy is one example. This policy is supported by a SHE management system and eight operational standards. The SHE management system has now been implemented at all our facilities and is audited regularly.



Progress against our previous short-term SHE Objectives for 2000

2000 Objectives	Progress
<p>Policy, Standards & Management System</p> <ul style="list-style-type: none"> Communicated, accepted and understood across the business by mid 2000 Implemented by end 2000 	<p>The System has been communicated to all parts of the company and has been fully implemented. There is a need for further improvement especially with the management of contractors, toll operators and suppliers.</p>
<p>The Reporting System (including the annual Management Review)</p> <ul style="list-style-type: none"> Fully operational by mid 2000 	<p>The majority of facilities implemented the reporting system. Work is now in progress to improve data quality.</p>
<p>Site Energy Efficiency</p> <ul style="list-style-type: none"> All sites to evaluate the potential for improving energy efficiency by the end 2000 Establish cost effective targets for improvement at local and corporate level 	<p>75% of facilities have reviewed energy consumption. Larger facilities have produced improvement plans and targets, which in some cases have already been implemented. Many of our smaller facilities consist of leased office accommodation but, we are nevertheless looking for continuous improvements across all areas.</p>
<p>Accidents, Incidents & Ill Health</p> <ul style="list-style-type: none"> Development of plans to ensure progress towards the goal of zero accidents, incidents and ill health throughout the company 	<p>The majority of facilities have either completed an initial improvement plan or are well advanced in its development.</p>

Health & Safety Performance

Ensuring the safety, health and wellbeing of employees and contractors is one of AstraZeneca's core corporate social responsibilities and an absolute priority for the company.

The AstraZeneca SHE management system [see page 5] represents an integrated approach to managing safety, health and environmental performance.

We have now implemented a common measurement and reporting system for SHE Performance across the company and 2000 will be the year against which our future performance will be compared.

AstraZeneca's Safety Performance

Fatalities

Regrettably, there were two fatal accidents involving AstraZeneca employees during 2000. One member of staff was killed in a road accident, and the second drowned while attending a conference.

In response to these unfortunate events we are re-emphasising our defensive driver training programmes and have issued specific health and safety guidance to our employees who attend conferences.



The growing US sales force is accomplishing their objective by incorporating a safe driving program into the training for new Pharmaceutical Sales specialists and District Sales Managers.


Accidents

In addition to the fatalities, there were 368 accidents that resulted in injury. The most common causes of injuries were slips, trips and falls, closely followed by vehicle and manual handling accidents. Details are shown in the chart.

Key data

Accident frequency rate:	4.2/million hours
--------------------------	-------------------

Accidents with Injury



Total Accidents with Injury in 2000: 370

Corporate Objectives 2001/2002

- Our goal is to have no accidents or incidents and to minimise our environmental impact. During 2001 we will identify the key areas where improvement is a priority and the most useful indicators to measure our progress. Progress against these Key Performance Indicators will be published from 2002 onwards.


AstraZeneca's Occupational Health Performance

There were 310 cases of work-related ill health reported during 2000. Upper-limb disorders (associated with computer workstations, manufacturing and laboratory activities) and work-related stress were the major sources of illness. Details are shown in the chart.

Key data

Occupational illness frequency rate:	3.5/million hours
--------------------------------------	-------------------

Occupational Illnesses



Total Instances of Occupational Illness in 2000: 310



Launched in June 2000, AstraZeneca do Brasil Ltda's "Well-being" programme is already producing results, with participants reporting personal benefits which are positively influencing their performance in the workplace.

- We will aim to improve the safety, health and wellbeing of all our employees by introducing behaviour-based programmes at all locations before July 1st 2002.

AstraZeneca's Approach to S H E

We believe that to improve our SHE performance we have to modify individual behaviour. Therefore, we will be promoting behavioural-based programmes at all our facilities. We aim to continue to improve the health, safety and wellbeing of all our employees and the sharing of examples of best practice.

The basis of our system is the recognition and management of risks to our business and our staff. We are developing a system which will assist our managers to identify priority areas and put in place appropriate systems to minimise the risks to our people, the environment and our business.

We have recognised that fire and natural hazards such as earthquake present some of the biggest risks. We are developing our processes to minimise the likelihood of these events having an adverse effect on our people and operations.

Another priority is to reduce musculo-skeletal risks in our laboratories, offices and manufacturing environments. We have set up cross-functional, international project teams to identify the main causes, develop common solutions and share best practice.

Our Senior Executive Team (SET) has recognised that modern business can place great pressure on individuals. They wish to promote programmes to help our staff at all levels across the company develop a healthy balance between life at work and life at home. Many local programmes are already in place and have been well received. The learning from these is being shared across the Company and it is intended that each facility should become involved in the programme. To encourage further participation and innovation, the most effective programme will receive a special award from the Chief Executive. There will also be an additional award for the best project on a specific theme, which for 2001 will be "Health and Wellbeing".

Employee **Development** and **Consultation**

AstraZeneca's continued success depends on our ability to attract and retain the best people.

We aim to promote a culture that values, recognises and rewards outstanding performance and in which employees share a commitment to AstraZeneca's objectives and to delivering their personal best. We encourage and support people in developing their potential to the full, against a background of equal opportunity where individual success is based solely on personal merit and performance.

All managers are responsible for agreeing a personal development plan tailored to the individual skills and aspirations of each member of their team. Everybody is expected to play an active part in drafting their personal development plan and identifying training needs.

This includes a programme to develop global leadership capabilities – implemented with the first 200 senior managers – which will be extended to more managers throughout 2001.

AstraZeneca's reward policy closely links individual reward with business performance at each level and ensures alignment of the company's, shareholders' and employees' interests. New, integrated reward and benefit schemes are designed to meet varied and changing employee needs around the world by introducing more choice and flexibility.

In the UK in 2001, for example, the company has introduced the 'AZ Advantage' flexible benefits scheme which gives employees the opportunity to tailor their reward package of cash and benefits to meet their individual needs.

We seek and listen to employee feedback. A global opinion survey, involving 22,500 people across the business was carried out in 2000 to benchmark opinion in the company's first year since merger. Positive feedback was given about the considerable progress the company has made relatively quickly to ensure that employees were clear about AstraZeneca's goals and targets, and people felt empowered and supported in their development.

The survey also emphasised the importance and need to improve the link between reward and recognition systems and performance. The challenge of managing heavy work-load and maintaining an appropriate home-work balance was also highlighted. These issues are being addressed across the company, as described above and in the Wellbeing section.

The full findings from the survey were communicated to employees worldwide – a selection of the findings are on our web site – www.astrazeneca.com



Wellbeing

AstraZeneca believes that healthy companies are made up of healthy people. The Wellbeing programme is designed to improve the physical and mental wellbeing of employees. The aim of the programme, which complements the existing occupational health and safety programmes, is to help employees develop their full potential and to be self confident and fulfilled. The programme is designed to help employees manage

work-related stress better and avoid potentially damaging effects.

Local Wellbeing programmes are well underway in Brazil, Canada, France, the Philippines, Sweden, UK and the US. These examples of best practice are being shared within the company to encourage similar initiatives in other locations.

Care and Use of Laboratory Animals

Animal testing plays an essential role in the development of new medicines and safety data derived from animal testing is required by regulatory authorities before new therapeutic agents can be tested on humans.

In our research and development of medicines for important areas of human healthcare, we use the most modern scientific knowledge and techniques available.

These include both animal studies and non-animal techniques. However, we aim to continue to reduce the number of laboratory animals by using available alternative methods such as computer modelling. We take our responsibility towards the animals we study very seriously and have a strict policy on the care and use of laboratory animals.

R&D Investment in Bangalore, India

AstraZeneca has announced plans for further investment in India to create a centre of excellence at its facility in Bangalore for the discovery and development of new medicines of importance to the developing world. The research centre will focus principally on finding a new treatment for tuberculosis. As a separate entity, AstraZeneca maintains an interest in the AZ Research Foundation, India, also located in Bangalore. Both organisations demonstrate our commitment to finding solutions to developing country diseases.


The Bangalore facility was originally set up in 1987 and the work of AZ R&D Bangalore is an integral part of AZ's R&D strategy. As part of a major investment programme in India, a new laboratory will be built to house the AZ R&D facility, close to the existing

AZ manufacturing site. Construction of the new facility, which will be completed by the end of 2002, will provide direct benefit to the local economy.

The choice of TB as the focus of research at Bangalore accords with the World Health Organisation's identification of 3 major targets for reducing the impact of developing country diseases. TB, along with malaria and HIV/AIDS, has been identified as a priority area for new medicines.

The research programme will involve collaborations with academe and shared expertise with AstraZeneca's genomics and research centres in Boston, USA and Alderley Park, UK.

The work will be reviewed by a Scientific Advisory Board that includes 3 leading academics from Stanford University, the Pasteur Institute and the WHO.



Bangalore, India



AstraZeneca has chosen TB as the focus of research at Bangalore. TB has been identified as a priority area for new medicines by the World Health Organisation for reducing the impact of developing country diseases

Environmental Performance

Benchmarking

We recognise the value of benchmarking, both internal and external, as a means of evaluating our performance and increasing our contribution to sustainable development. We have compared our emissions and consumption data with the values shown in the environmental reports of other leading pharmaceutical sector companies. The results indicate that AstraZeneca's impact is consistently below the sector average. However, direct comparison is difficult because of the differences in product portfolios and the processes used by the different companies. For details see our web site www.astrazeneca.com

We are keen to develop this activity further and participate in leading benchmarking schemes, for example the UK Business in the Environment Index, and to develop a common index for the comparison of information

Use of resources

Waste

Most of our active pharmaceutical products are manufactured using synthetic chemistry. The majority of the waste we generate contains chemicals and solvents used in these processes together with materials generated during formulation and packing operations. We also treat many of our wastewater streams using on-site biological treatment. The amounts of waste from these processes are included in our figures together with our general waste.

We classify our waste as either hazardous or non hazardous according to the legislation in the country in which they are generated.

We believe that efficient use of resources and


recycling helps conserve natural resources, reduces waste and saves money.

AstraZeneca's Approach to S H E

Whilst a certain amount of waste is inevitable, waste generation implies inefficient and costly use of raw materials and avoidable waste disposal costs. Therefore, efficient processes and re-use and recovery of materials are priorities for us. Recycling of polyethylene and polypropylene packaging waste from our manufacturing facilities has increased significantly. The material is sent to companies outside AstraZeneca which recycle a wide range of plastic raw materials.


Where possible we avoid the use of hazardous

Hazardous Waste



Total Hazardous Waste Produced in 2000: 31,000 tonnes

Other Waste



Total Other Waste Produced in 2000: 30,000 tonnes

substances and disposals to landfill. Wherever possible, we treat waste so that it can be disposed of safely and with minimal impact on the environment.

Key data

Parameter	Output (tonnes)	Recycled (%)	Index (g/\$ sales)
Total hazardous waste	31,000	2	2
Total other waste	30,000	27	2

Water Use

AstraZeneca used 5.3 million m³ of water in 2000 (0.3 litres/\$ sales). We recognise that water is a valuable natural resource which we can help to conserve through efficient use and recycling.

AstraZeneca's Approach to S H E

We are assessing the use of water throughout our operations with priority being given to those regions where water resources are scarce. Where possible, we are introducing water-saving programmes, for example in Australia our manufacturing facility has reduced water consumption by 40,000 litres a day.

Discharges to the Environment

Water

All our facilities discharge wastewater that is treated, either on site or by the local sewage works. The discharges are all subject to permits issued by local authorities. Whilst we currently comply with all these permits, it is our policy wherever possible to minimise discharges to the environment.

Key data

Parameter	Output (tonnes)	Index (mg/\$ sales)
Phosphorus discharged	66	4
Nitrogen discharged	62	4
Chemical Oxygen Demand	1,500	95

AstraZeneca's Approach to S H E

As part of our process of continuous improvement, we are upgrading effluent treatment at our manufacturing facilities. For example, we are making a major investment to install on-site waste water treatment at our Avlon facility in the UK.

Air

Our operations result in a range of air emissions. These include VOCs from our manufacturing operations, CO₂ from the generation of the energy that we use and from transport and CFCs, HCFCs and HFCs arising from the propellants used in our products and from our manufacturing facilities.

Key data

Parameter	Output (tonnes)	Index (mg/\$ sales)
Total VOCs emitted to air	365	23
Total CFC 11 equivalents emitted to air during manufacturing	0.4	0.03

During 2000 we used about 14,000 tonnes of solvents of which 1,100 tonnes were halogenated. We have implemented processes for recovery, reuse and recycling with the result that total emissions were reduced to about 365 tonnes, of which about 30 tonnes were halogenated.


We used about 8 tonnes of CFCs, 3 tonnes of HCFCs and less than 0.5 tonnes of HFCs in 2000. Only a small fraction of these were emitted as a result of manufacturing processes. The ozone-depleting potential of all substances emitted during manufacturing was equivalent to 0.4 tonnes of CFC 11.

AstraZeneca's Approach to S H E

We are continuing to reduce VOC emissions from our facilities. Replacement or upgrading of existing abatement plants has significantly reduced emissions already. We are gradually replacing the CFCs that are still used with compounds which have minimal or substantially lower ozone-depleting potential.

The largest contribution to our total CFC emissions is from propellant gases that are lost when patients use our inhalers. We have been very active in the development of alternatives to CFC-driven inhalers (see chart) and this work is continuing.

Percentage of Inhalation Products with CFC Propellants



Energy & Global Warming

Global warming is an increasingly important issue for governments and society. Carbon dioxide (CO₂), considered the principal global warming gas, is formed when fossil fuels are burnt to produce energy for our processes and to heat and light our facilities. It is also generated by the vehicles and aircraft we use to transport our products and people.


Key data

Parameter	Output	Index
Total energy use	1,950 (GWh)	0.12 (kWh/\$ sales)
Total CO ₂ emissions from energy use	0.64 (M tonnes)	0.04 (kg/\$ sales)

AstraZeneca's Approach to S H E

We are constantly looking for ways to improve energy efficiency and reduce CO₂ emissions, to save the business money and to lower our environmental impact. Energy management programmes, group and local targets, new technology (such as combined heat and power plants) and increased awareness among employees will help us meet our objective on CO₂ emissions

Energy by Source



Total Energy Use in 2000: 1,950 Gigawatt hours (GWh)

CO₂ Emissions from Energy Use



Total CO₂ Emissions from Energy Use in 2000: 0.64 Million tonnes (M te)

Transport


In a complex global organisation such as AstraZeneca, it is difficult to produce precise data for transport-related CO₂ emissions. The following figures are our best estimates.

Key data

Parameter	Output (M tonnes)	Index (kg/\$ sales)
Total CO ₂ emissions from transport	0.26	0.02

Business air travel in 2000 contributed about 0.1 million tonnes of CO₂. Much of this was due to increased travel associated with the company merger and the figure should decrease in future. Business travel by car amounted to 339 million kilometres, most of this associated with sales and marketing. Product distribution by road contributes least to our total CO₂ emissions.

CO₂ Emissions from Transport



Total CO₂ Emissions from Transport in 2000: 0.26 Million tonnes (M te)

AstraZeneca's Approach to S H E

By encouraging the use of telephone and video conferencing throughout the business we are aiming to reduce the total distance our employees travel every year. We are reviewing our distribution network with a view to increasing the efficiency of the transport of our products.

Compliance

Whilst compliance with national legislation and our permits was generally very good, there were ten incidents of non-compliance with operating permits in 2000. Seven of the ten incidents were associated with breaches of emissions and discharge permits. Although regrettable, these incidents did not lead to any significant damage. However, although AstraZeneca was not prosecuted, there is a possibility that one site may face legal action for exceeding its consent to discharge methylene chloride.

The other three involved failures to obtain appropriate permits or submit information to regulatory authorities. The causes have been identified and action plans agreed with the regulatory authorities

Pharmaceuticals in the Environment

The manufacture of pharmaceuticals is very highly regulated and we aim to minimise the amounts of any of our products being released to the environment in effluent discharges from our facilities. However, we also recognise that small quantities of our products, excreted by patients, may enter the environment.

Improvements in analytical techniques have now made it possible to detect very small concentrations of some pharmaceuticals in the waste waters discharged from sewage treatment plants. There have also been reports of some widely used drugs being found in river waters and sea waters.

AstraZeneca assesses the environmental fate and

effects of both its products and processes in line with regulatory requirements for new drug applications. Based on our current information, we do not believe that there is any significant risk to either people or the environment. In the vast majority of cases, the levels of drug residues detected in the environment are many times less than the minimum concentrations expected to cause any significant environmental effects. However, we are following developments in this area very closely. We are continuing to invest in advanced waste treatment at our facilities and to collaborate with regulatory agencies, academics and trade associations throughout the world on this topic.

Other Issues

Our operations have a number of additional environmental impacts. For further details on these and the issues already discussed, plus information on Land Use & Restoration and Products & Packaging, please visit our website at www.astrazeneca.com.

Corporate Objective 2001/2002:

- We will aim to achieve a reduction in the growth of CO₂ emissions from our facilities by 2005 – this will be by an amount equivalent to 20% of 1998 emissions.

Chief Executive's Awards for Outstanding Safety, Health and Environmental Performance

On announcing the SHE awards for this year, Tom McKillop said that he was very encouraged by the dedication and inventiveness of people throughout the Business in delivering projects which provided the basis for very real improvements in our SHE performance. "We have to look for new solutions to old challenges if we are to meet our aspirational goal of zero accidents and incidents" he said.

Over eighty projects had been entered. These had come from fifteen countries and represented all parts of the business. Dr McKillop personally made the final selection from the short list presented by the awards panel. This year the trophy was awarded to AstraZeneca Canada for a series of related projects that together improve the management and visibility of Safety, Health and Environmental Performance. The projects included the development and implementation of a local management system, management of contractors, driving safety and a programme for personal fitness. These were supported by a campaign to raise the awareness of SHE issues across the Company. "I was especially pleased to see the importance that

the managers placed on improving an already good SHE performance whilst delivering an outstanding business performance" said Dr McKillop.

In addition to the trophy, three sites received "Highly Commended Certificates".

Brazil, for its programme of re-assessing the local SHE issues and developing an integrated programme for the National Marketing and Manufacturing Operations.

UK Sales, for its project which focussed on promoting safety at national sales conferences. Particular emphasis had been put on the importance of safe travel, personal security and sensible drinking.

Two contractors at Avlon Works UK were recognised for the systems they had put in place to raise the importance of SHE among their own workforce together with the provision of training and auditing performance in the workplace.

Each of the winners also received a donation of £2,000 for the charity of their choice.

Further details of the CE awards are available on our web-site www.astrazeneca.com.

"I was especially pleased to see the importance that the managers placed on improving an already good SHE performance whilst delivering an outstanding business performance"



This year the trophy was awarded to AstraZeneca Canada for a series of related projects that together improve the management and visibility of Safety, Health and Environmental Performance.

Policy & Code of Conduct

SHE Policy

Good SHE performance is essential for continued business success. Considering the SHE-related impact of all our activities is a fundamental part of our operation. Our SHE policy, detailed below, reflects this commitment, and sets out the baseline requirements for our worldwide performance.

Agreed by our Board of Directors, it applies to all employees and all activities, and compliance is mandatory. To ensure compliance, the policy is supported by a SHE management system and eight operational standards (see page 5).

Our mission is to be first for innovation and value in the provision of products and services to improve human health and quality of life. Safety, Health and Environmental (SHE) considerations are core to this and all our activities shall take account of social, environmental and economic factors, so as to:

- Meet or exceed legal requirements, regulations and international agreements.
- Create a culture where SHE considerations are integrated into all activities across the group.
- Conduct business as a responsible corporate member of society committed to continual improvements in all aspects of our SHE performance.
- Provide a safe and healthy work environment for all our employees.
- Economise on the use of natural resources and work to minimise the impact on the environment.
- Aim to eliminate all injuries and incidents.
- Be amongst the industry leaders in SHE performance.
- Provide information on our SHE performance and communicate openly with all interested parties.

Code of Conduct

We place the highest value on the reputation of the AstraZeneca Group. We aim to earn the trust and confidence of everyone we deal with by maintaining high ethical standards at all times.

At the heart of our commitment is the AstraZeneca Code of Conduct, published in June 2000, with which all our employees are required to comply both in spirit and letter. Integrity, honesty, diligence and care are cornerstones of the Code.

The Code covers the following areas:

- Compliance
- Business practices
- Equal opportunities
- Personal harassment
- Political contributions
- Conflicts of interest
- Insider information
- Group property and resources
- Group policies, delegated authorities and reserved powers.

The Code of Conduct and the Policy & Standards can be downloaded from our website at www.astrazeneca.com, or you can contact us directly for a printed copy. Please find contact details overleaf.

Contact information

Thank you for taking the time to read our report – we hope you have found it informative. Further information can be found on our website at www.astrazeneca.com. Requests for information and comments can also be sent to Corporate Affairs Department at Stanhope Gate, London (see below) or via e-mail to CSR@astrazeneca.com

**Registered office
and corporate headquarters address:**

AstraZeneca PLC
15 Stanhope Gate
London W1K 1LN
UK
Tel: +44 (0)20 7304 5000
Fax: +44 (0)20 7304 5183

R&D headquarters address:

AstraZeneca R&D Södertälje
S-151 85 Södertälje
Sweden
Tel: +46 (0)8 553 260 00
Fax: +46 (0)8 553 290 00

Investor relations contacts:

UK and Sweden: As above or e-mail:
investor-relations@astrazeneca.com
US:
Investor Relations
AstraZeneca LP
1800 Concord Pike
PO Box 15438
Wilmington
DE 19850-5438
US
Tel: +1 (302) 886 3000
Fax: +1 (302) 886 2972